Want to see PURE full AI Analyst Report?
Pure Bioscience (PURE) AI Stock Analysis
Pure Bioscience
(Other OTC:PURE)
The score is held down primarily by very weak financial performance—persistent large losses, ongoing cash burn, and a strained capital structure with negative equity and higher leverage. Technicals provide only modest support with a mild uptrend and neutral momentum indicators. Valuation is constrained by negative earnings and no dividend, while the recent insider financing helps liquidity but also highlights dilution and continuing capital needs.
Pure Bioscience (PURE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 31.85K
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- -0.61
- Revenue Growth
- 5.27%
- EPS Growth
- -0.47%
- Country
- US
- Employees
- 12
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Chemicals
Pure Bioscience Business Overview & Revenue Model
Company Description
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform co...
Pure Bioscience Financial Statement Overview
Summary
Financial performance is very weak: revenue is small and volatile, operating and net losses remain deeply negative (losses exceed revenue), and cash flow is persistently negative with ongoing free-cash-flow burn. The balance sheet is a major risk with deeply negative equity since 2024 and rising leverage, despite some narrowing of losses versus 2023–2024.
Income Statement
14Very NegativeBalance Sheet
9Very NegativeCash Flow
11Very Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.32M | 2.32M | 2.20M | 1.96M | 1.88M | 1.85M |
| Gross Profit | 1.33M | 1.33M | 1.30M | 1.15M | 971.00K | 1.00M |
| EBITDA | -2.07M | -2.08M | -2.10M | -3.05M | -3.83M | -3.27M |
| Net Income | -2.48M | -2.48M | -2.40M | -3.35M | -3.96M | -3.50M |
Balance Sheet | ||||||
| Total Assets | 1.19M | 1.19M | 1.06M | 818.00K | 1.82M | 4.48M |
| Cash, Cash Equivalents and Short-Term Investments | 569.00K | 569.00K | 334.00M | 349.00K | 1.09M | 3.39M |
| Total Debt | 6.60M | 6.60M | 523.60K | 2.95M | 1.02M | 0 |
| Total Liabilities | 7.59M | 7.59M | 6.17M | 3.68M | 1.55M | 575.00K |
| Stockholders Equity | -6.40M | -6.40M | -5.12M | -2.86M | 272.00K | 3.91M |
Cash Flow | ||||||
| Free Cash Flow | -1.74M | -1.74M | -2.02M | -2.53M | -3.31M | -2.50M |
| Operating Cash Flow | -1.74M | -1.74M | -2.02M | -2.53M | -3.28M | -2.42M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -33.00K | -81.00K |
| Financing Cash Flow | 1.97M | 1.97M | 2.00M | 1.78M | 1.01M | 3.50M |
Pure Bioscience Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PURE, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.41 is Neutral, neither overbought nor oversold. The STOCH value of 18.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PURE.
Pure Bioscience Risk Analysis
Pure Bioscience disclosed 39 risk factors in its most recent earnings report. Pure Bioscience reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPure Bioscience Peers Comparison
Overall Rating
UG77Outperform
MTEX50Neutral
TANH49Neutral
GROV48Neutral
TKLF47Neutral- PURE45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| UG | 77Outperform | $31.38M | 12.70 | 22.24% | 8.02% | 3.23% | -3.58% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| MTEX | 50Neutral | $16.68M | -2.21 | 336.75% | ― | -4.97% | -91.06% |
| TANH | 49Neutral | $9.77M | -35.07 | -24.71% | ― | -10.67% | -83.85% |
| GROV | 48Neutral | $47.40M | -5.72 | -83.49% | ― | -14.25% | 66.08% |
| TKLF | 47Neutral | $6.22M | 0.81 | 1.71% | 13.87% | 77.22% | -89.32% |
| PURE | 45Neutral | $9.10M | -3.04 | 41.29% | ― | 5.27% | -0.47% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PURE | Pure Bioscience | 0.07 | 0.01 | 25.00% | |
| MTEX | Mannatech Inc | 8.64 | -0.36 | -4.00% | |
| UG | United-guardian | 6.86 | 0.76 | 12.48% | |
| TANH | Tantech Holdings Ltd. | 14.50 | -44.00 | -75.21% | |
| GROV | Grove Collaborative Holdings, Inc. | 1.11 | -0.25 | -18.38% | |
| TKLF | Yoshitsu Co. Ltd. Sponsored ADR | 1.37 | -1.70 | -55.37% |
Pure Bioscience Corporate Events
PURE Bioscience completes insider-led private equity financing
PositiveOn October 15, 2026, PURE Bioscience, Inc. completed a private placement financing with accredited investors, raising $555,000 through the issuance of 10,183,486 shares of common stock at $0.0545 per share. Board member Tom Y. Lee provided the full f...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026